ophthalmologytimes6h
Researchers offer insights into wet AMD: Study reveals potential to enhance anti-VEGF therapy with experimental drug to preserve vision
A Johns Hopkins study reveals that anti-VEGF treatments for wet AMD may unintentionally elevate ANGPTL4, a protein that ...
ophthalmologytimes1d
Formosa Pharmaceuticals announces top-line results from Chinese trial evaluating APP13007
Formosa Pharmaceuticals has announced the completion and top-line results from CPN-303, a phase 3 clinical study of APP13007 ...
ophthalmologytimes2d
FDA grants fast track status to FELIQS’ FLQ-101 for ROP
FELIQS plans to conduct a Phase 1b/2 study of FLQ-101 (tROPhy-1 study) both in the US and Japan in the first quarter of 2025.
ophthalmologytimes2d
Study: Aromatherapy decreased postoperative patient anxiety and pain associated with oculoplastic surgery
The investigators conducted a randomized controlled trial of 60 patients who underwent monitored anesthesia care sedation for ...
ophthalmologytimes2d
LumiThera’s Valeda Light Delivery System receives marketing authorization from FDA
The Valeda Light Delivery System is for the treatment of patients with dry age-related macular degeneration (AMD).
ophthalmologytimes1d
Adapting glaucoma training and treatment: Insights from the Orbis Flying Eye Hospital
Omar Salamanca, MD, staff ophthalmologist, Orbis Flying Eye Hospital, discusses Orbis's tailored glaucoma training programs, which focus on hands-on surgical skills, early detection, telemedicine, and ...
ophthalmologytimes4d
Caffeine's effect on retinal vessel density
200 mg of caffeine elevated the blood pressure after 2 hours but did not impact the retinal VD.
ophthalmologytimes2d
Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD
Robert T. Chang, MD, from Stanford University discusses how large language models are transforming ophthalmology by enhancing ...
ophthalmologytimes8d
Researchers receive $6.4 million grant from NEI to seek new treatment for blindness-causing diseases
Rensselaer researchers receive $6.4 million grant from NEI to seek new treatment for blindness-causing diseases.
ophthalmologytimes8d
Dropless cataract surgery: Shifting paradigm in postoperative care
Dropless cataract surgery eliminates postoperative eye drops, enhancing patient adherence and reducing complications like ...
ophthalmologytimes7d
Innovation Series: Expanding access to eye care, advice for aspiring innovators from DMEI ophthalmology residents (part 3)
In this final episode, DMEI’s residents share their future plans for expanding the device capabilities and offer practical ...
ophthalmologytimes2d
Phase 3 LUGANO Trial explores EYP-1901’s potential to reduce treatment burden in wet AMD Patients
In an interview with David Hutton of Ophthalmology Times, Ash Abbey, MD, discusses the Phase 3 LUGANO trial for EYP-1901 in treating wet age-related macular degeneration. Abbey discusses the trial’s ...